Metagenomi Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2022 | — | $-74.4M | $190.5M |
| Mar 2023 | — | $-90.0M | $95.7M |
| Jun 2023 | — | $-102.5M | $51.6M |
| Sep 2023 | — | $-119.0K | $101.9M |
| Dec 2023 | — | $-135.6M | $140.6M |
| Mar 2024 | — | $275.6M | $102.6M |
| Jun 2024 | — | $269.4M | $61.2M |
| Sep 2024 | — | $255.8M | $25.1M |
| Dec 2024 | — | $234.9M | $27.4M |
| Mar 2025 | — | $212.7M | $29.2M |
| Jun 2025 | — | $195.8M | $26.9M |
| Sep 2025 | — | $178.4M | $32.8M |
| Dec 2025 | — | $158.6M | $41.7M |
| Mar 2026 | — | $137.8M | $25.3M |
| Jun 2026 | — | $112.6M | $39.0M |